Two hundred and twenty two hyperlipidemic @entity1 were recruited for a 12-week prospective, multicenter, open-label, titrate-to-goal study to evaluate the efficacy and safety of 20 to 40 mg per day of @entity3413 in a Thai population. The efficacy on lipid lowering was evaluated at 4 weeks and 8 weeks after medication. Based on NCEP ATP II guideline and ADA position statement, subjects were categorized into three groups according to LDL-C goals; group I: @entity1 without CHD and with < 2 CHD risk factors, group II: @entity1 without CHD and with > or = 2 CHD risk factors and group III: CHD @entity1 or @entity6 @entity1 with > or = 1 risk factors. Significant changes of all lipid parameters from baselines were noted at 4 weeks after medication except for HDL-C levels. Reduction of serum LDL-C, TC and TG by 40 per cent, 29 per cent and 16 per cent respectively and increase of serum HDL-C by 5 per cent were observed at 8 weeks of therapy (p<0.05). At 4 weeks after taking @entity3413 20 mg/day, 78.9 per cent of @entity1 in group I, 67.4 per cent in group II and 40.9 per cent in group III achieved LDL-C goals. Seventeen per cent of the @entity1 who were evaluated at 8 weeks increased the @entity3413 dosage to 40 mg per day in the second month of treatment. At 8 weeks of therapy with @entity3413 20-40 mg/day, 90.1 per cent of @entity1 in group I, 77.4 per cent in group II and 66.7 per cent in group III achieved LDL-C goals. Adverse symptoms during therapy, mostly mild, developed in 6.3 per cent of the 222 @entity1 . CONCLUSION: @entity3413 20-40 mg/day was effective and well tolerated in managing lipid parameters in Thai @entity1 similar to other ethnic populations.

Dose-expanded study in the reinforcement of efficacy of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3413 :: ('MESH:D019821', 'Chemical') :: ['Simvastatin', 'simvastatin'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic']
@entity3413 :: (MESH:D019821,Chemical) :: ['simvastatin']
